FDA imposes clinical hold on Inhibikase's IkT-148009 Parkinson's and MSA programs

Inhibikase Therapeutics, Inc.

FDA placed a clinical hold on the IkT-148009 201 program in Parkinson's disease and its use in Multiple Systems Atrophy (MSA).
Inhibikase states no serious adverse events have been observed in the ongoing 201 trial to date.
Official clinical hold letter expected within 30 days; company is actively working with FDA to resolve concerns.
IkT-148009 is a protein kinase inhibitor for neurodegenerative diseases; no timeline for hold resolution given.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.